SOCIETY FOR NEUROSCIENCE for SOCIETY FOR NEUROSCIENCE
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
for both FY22 and FY 23 - advocated for continued predictable funds for NIH, NSF, BRAIN Initiative and VA medical and prosthetic research programs and asked Congress not to rely on continuing resolution; advocated for the RISE Act - in ensure funding to restart and reopen biomedical research labs that were impacted but the COVID-19 pandemic shutdowns. Additionally, provided input to congressional offices on the policy development process of ARPA-H.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GRADY | — |
Animals ANI
for both FY22 and FY23 - advocated for the ethical and responsible use of animals in biomedical research. Specifically, promoting report language for the FY22 LHHS bill to include the importance of animal research, primarily non-human primates (NHPs), used in the COVID-19 vaccine and other discoveries; additionally promoting report language for the FY23 LHHS bill to include the use of NHPs in long haul COVID-19 neuroscience research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GRADY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.